ASX RELEASE

ASX Code: ESE 14 March 2018

ESENSE-LAB REPORTS ANOTHER MAJOR PROGRESS IN R&D

- **Major progress in R&D shows a clear anti-inflammatory activity with the Company's terpenes strains**
- **Strengthens eSense penetration to the medical cannabis markets**
- **Significantly strengthens eSense's IP**
- **Opens new revenue generating markets**

Life sciences company **eSense-Lab Ltd ("eSense" or the "Company") (ASX: ESE)** is pleased to announce it has achieved an excellent progress in its Research and Development ("R&D") activity demonstrating a robust anti-inflammatory activity for its medical cannabis terpene blends.

Inflammation is the response of our body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. Once one of the above stimulations occurs our body initiate a cascade of inflammatory related actions including the recruitment of immune cells to the injured tissue. Such recruitment involves cytokine secretion, cell migration and penetration of body fluids accompanied with feeling of pain, swelling, redness and burn. Inflammation could be a passing occurrence once the body managed to control the harmful stimulation by exerting termination signals. Yet, if the body is not strong enough to terminate the inflammation it can be developed in to a chronic one with permanent tissue destruction and constant pain. Thus, aiding the body in terminating or at list suppressing inflammation is the key mechanism to reduce tissue destruction and ameliorate the suffer and pain.

eSense conducted a serial of testing for an anti-inflammatory activity across its medical cannabis terpene blends including Girl Scout Cookies, OG-Kush, Sour Diesel, Jack Herer, Daniel, Super Lemon Haze, Gorilla Glue, Chees and Granddaddy Purple.

Macrophages cells were stimulated with an inflammatory stimulant and tested for the secretion of inflammatory cytokines (TNF-Alpha and Nitric Oxide) in the presence or absence of eSense's terpene blends. A clear and robust anti-inflammatory effect could be seen in the presence of 6 out of the 9 tested blends manifested by a dose response suppression of cytokine secretion. Blends such as OG-Kush, Sour diesel, Granddaddy purple, Daniel and OG-kush managed to supress cytokine secretion up to 90%.

"*Once again, our R&D team achieving new heights with new developments and accomplishments we can commercialise" Comment on the developments, eSense CEO Haim Cohen "Our team of managers and R&D are all enthusiastic about this achievement and looking forward for a commercialize of these abilities generating another revenue stream for eSense-Lab*"

FOR FURTHER INFORMATION:

Company Secretary
Ian Pamensky
+61 414 864 746
ian@cfo2grow.com.au

Investor/media relations
Matthew Wright
+61 451 896 420
matt@nwrcommunications.com.au

About eSense-Lab

eSense-Lab Ltd (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense–Lab can then use this model to 'reverse engineer' a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant's health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost

To learn more about eSense-Lab, visit www.esense-lab.com